We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Slacking On Post-Approval Follow-Up: Report

Law360 (July 11, 2006, 12:00 AM EDT) -- As concern over drug safety regulation and procedures continues to mount, a newly-released report by the inspector general of the U.S. Health and Human Services Department points the finger of blame at the U.S. Food and Drug Administration.

The report accuses the agency of failing to track the status of many post-approval safety studies.

All new drugs are required by the FDA to undergo clinical testing to demonstrate their safety prior to approval for sale in the U.S., but these mandatory pre-market trials involve relatively small...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.